Circulating microRNA expression profiling and bioinformatics analysis of patients with coronary artery disease by RNA sequencing

Zhixiong Zhong1,2,3,4 | Wei Zhong1,2,3,4 | Qifeng Zhang1,2,3,4 | Qunji Zhang2,3,4,5,6 | Zhikang Yu2,3,4,5,6 | Heming Wu2,3,4,5,6

1Center for Cardiovascular Diseases, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China
2Guangdong Provincial Key Laboratory of Precision Medicine, Clinical and Translational Research in Hakka Population, Meizhou, China
3Guangdong Provincial Engineering and Technology Research Center for Molecular Diagnostics of Cardiovascular Diseases, Meizhou, China
4Meizhou Municipal Engineering and Technology Research Center for Molecular Diagnostics of Cardiovascular Diseases, Meizhou, China
5Meizhou Municipal Engineering and Technology Research Center for Molecular Diagnostics of Major Genetic Disorders, Meizhou, China
6Center for Precision Medicine, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China

Abstract

Background: MicroRNAs play a vital role in coronary artery disease. Abnormal expression of microRNAs has been found to be associated with the occurrence of CAD.

Methods: We identified significantly differentially expressed microRNAs in plasma between 40 patients with CAD and 10 controls with NCA using RNA sequencing. The differentially expressed microRNAs were analyzed for Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment.

Results: Fifty cDNA libraries were constructed and sequenced, and a total of 1871.82 M raw reads were obtained, and 2135 microRNAs were found. Compared to the expressed microRNAs of NCA controls, 159 microRNAs were differentially expressed in CAD patients, including 119 upregulated microRNAs and 40 downregulated microRNAs. The top 10 upregulated miRNAs were miR-144-3p, miR-34a-5p, miR-15b-3p, miR-22-3p, miR-29b-3p, miR-1270, miR-6891-5p, miR-106a-5p, miR-15b-5p, and hsa-miR-499b-3p. The top ten downregulated miRNAs were miR-4437, miR-6842-3p, miR-4664-3p, miR-671-3p, miR-219a-1-3p, miR-7848-3p, miR-664a-3p, miR-1284, miR-361-3p, and miR-6780a-5p. The target genes of differentially expressed microRNAs were related to many basic biological terms, such as biological process, cellular component, and molecular function. According to the KEGG pathway analysis, the most enriched pathways of the differentially expressed microRNAs...
were endocytosis, focal adhesion, axon guidance, and so on. Furthermore, six upregulated and two downregulated microRNAs were detected by qRT-PCR (Quantitative Real-time PCR) and ROC analysis for diagnosing CAD.

**Conclusion:** The results suggest that the expression levels of some microRNAs may play a vital role in the physiological and pathological course of CAD. Our study may provide useful information for the diagnosis and treatment of CAD.

**KEYWORDS**
Chinese, circulating microRNA, coronary artery disease, expression profiles, Hakka

### 1 | INTRODUCTION

Coronary artery disease (CAD) is a common heart disease. It is a myocardial malfunction and structural lesion caused by coronary artery stenosis and poor blood supply. The occurrence of CAD is closely related to the degree and number of coronary artery stenoses. Hypertension, diabetes, obesity, smoking, and drinking are the main factors that induce this disease. Clinically, it is often divided into stable angina (SA) and acute coronary syndrome (ACS). ACS can be divided into unstable angina (UA), acute non-ST-segment elevation myocardial infarction (NSTEMI) and acute ST-segment elevation myocardial infarction (STEMI), according to severity. STEMI and NSTEMI are together known as acute myocardial infarction (AMI).

Coronary artery disease is one of the most fatal diseases in the world. Atherosclerosis plays a pivotal role in the occurrence and progression of CAD. It is strongly associated with arterial stenosis because of the accumulation of atheromatous plaque, adipopexis, and extracellular matrix. Coronary thrombosis often leads to acute coronary events. Inflammation is involved in various stages of the formation and development of atherogenesis plaque, and inflammatory factors produced in this process are predicted to be potential markers of CAD. They play a key role in coordinating the interactions of the cells during the development of atherogenesis. Inflammatory mediators involved in the function of some cells, including endothelial cells, macrophages, and T cells. They stimulate some signalling pathways in the onset and progression of atherosclerosis. They can be regulated by microRNAs (miRNAs), which are small non-coding RNAs that have emerged as important regulators in atherosclerosis.

MicroRNAs are a class of single-strand, non-coding RNAs with a length of 18-22 bp that play a vital regulatory role in different cell development processes by downregulating the expression of their target genes. The analysis of the expression of microRNA in blood, tissue, or cell samples provides important information for the study of the biological functions of these molecules. In recent years, researchers have developed many methods to detect the differences in the expression of microRNAs in some physiological and pathological processes, and they have found that the abnormal expression of microRNAs is connected with the occurrence of cancer, nervous disorders, diabetes, and heart diseases. Many studies have shown that microRNAs have some important regulatory effects in the cardiovascular system, including the heart, inflammatory response, angiogenesis, and metabolism. Abnormal expression of microRNAs has been found to be related to the occurrence of CAD.

In this study, the differential expression of microRNAs in CAD patients and normal coronary artery (NCA) controls was detected by high-throughput sequencing. We explored the role of microRNAs in CAD, and we further explored the relationship between microRNAs and the onset and progression of CAD to provide new ideas for the diagnosis and treatment of CAD.

### 2 | MATERIALS AND METHODS

#### 2.1 | Study subjects

Between February 2016 and April 2017, angiographically confirmed CAD patients and NCA controls were prospectively enrolled in this study from the Department of Cardiovascular Diseases in Meizhou Peoples’ Hospital. The diagnosis of CAD was based on the ACC/AHA classification. To be eligible, the patients had to have more than or equal to 50% diameter stenosis in the epicardial coronary arteries. Other inclusion criteria: chest pain, ischemic changes in electrocardiograph (ECG), and increased myocardial enzymes. All subjects underwent coronary angiography to confirm the diagnosis. Exclusion criteria: aortic dissection, ejection fraction less than 20%, pulmonary embolism, tumor, infectious or autoimmune diseases, incontinence, severe renal dysfunction (creatinine value > 265 μmol/L), a recent surgical procedure, liver dysfunction, and blood-borne infectious diseases, including HIV/AIDS, HBV, and HCV. Patients with myocarditis, pericarditis, and cardiomyopathy were also excluded.

Fifty subjects, 35 males and 15 females (2.3:1), were included in this study. They were classified into 5 groups: normal coronary artery (NCA), SA, UA, NSTEMI, and STEMI. The AMI patients presented ischemic chest pain, elevated levels of cardiac enzymes, and ST-T changes. The UA patients had angina, with irregular angina at rest, and no rise in troponin. The SA patients had stable angina, lasting up to 10 minutes. In each group, two physicians independently confirmed the angiographic data. This study was approved by the Human Ethics Committees of Meizhou People's Hospital, Guangdong Province, China and followed the Helsinki Declaration. Informed consent was obtained from all subjects in this study.
2.2 | Sample collection and processing

Two samples were taken before the coronary angiography surgery, one for the extraction of whole-blood RNA and one for the detection of BNP and cTnI. Peripheral blood samples (6 mL) were taken from the anterior elbow vein using EDTA anticoagulant tubes, mixed gently up and down for 10 times, saved at 4°C, and subjected to plasma separation within 1 hour. The blood samples were centrifuged at 800 g for 10 minutes, and the plasma was transferred to a 1.5 mL centrifuge tube (RNase-free). Total RNA was obtained with an RNeasy Kit (TianGene), and RNA integrity was assessed using an Agilent Bioanalyzer 2100 system (Agilent Technologies).

2.3 | Library construction and high-throughput sequencing

After screening test samples, a library of small RNAs was constructed using an Illumina TruSeq Small RNA Sample Prep Kit, which directly added joints to the small RNA using the 3' and 5' end special structures (5' end phosphate group, complete 3' end hydroxyl). The RNA was then reverse-transcribed to cDNA. The target DNA fragments after PCR were separated by PAGE, and the cDNA libraries were recovered by recycling and purifying.

After the libraries were constructed, the libraries were preliminarily quantified by Qubit2.0 and diluted to 1 ng/µL. Then, the insert size of the libraries was detected by the Agilent 2100. If the insert size was in line with expectations, accurate quantification was carried out by qPCR to confirm the effective concentration of libraries (>2 mmol/L) to ensure the quality of the libraries. Sequencing libraries were constructed and confirmed, and the different libraries were sequenced according to the requirements, which was performed on an Illumina HiSeq 2500.

2.4 | Identification of differentially expressed genes

The raw reads in FASTQ format were filtered to remove the adapter sequences, poly-N sequences, and low-quality sequences before data analysis. The remaining reads were also called "clean reads" and were acquired for transcriptome assembly and quantification. Next, the index of the reference genome was built using Bowtie v2.0.6, and paired-end clean reads were mapped to the reference genome using TopHat v2.0.9. Transcriptome assemblies were generated using Cufflinks v2.1.1 with the default parameters. The microRNA sequence reads of each sample were normalized to fragments per kilobase of transcript per million mapped reads (FPKM) values using Cuffdiff v2.1.1. The P value and fold change were calculated for each gene. \( P < .05 \) and \( \log_2(\text{fold change}) > 1 \) were set as the combined threshold for significantly differential expression.

2.5 | Gene ontology and KEGG enrichment analysis

Gene ontology analysis was carried out to determine the potential biological process terms of the differentially expressed genes in GO annotations. Pathway analysis was utilized to find the significant pathways of the differentially expressed genes according to the KEGG database. Fisher’s exact test was applied to evaluate whether the GO terms or the KEGG pathways were enriched among the differentially expressed genes, and \( P < .05 \) was set as the threshold for.

2.6 | Quantitative real-time PCR

To verify the reliability of the RNA sequencing data, some microRNAs with differential expression were detected by qRT-PCR. Total RNA in the plasma was extracted using an RNeasy Kit (TianGene) and was reverse-transcribed to cDNA. qPCR was performed using the following conditions on the LightCycler 480 (Roche): 10 minutes at 95°C, then 40 cycles of amplification (2 seconds at 95°C for denaturation, 20 seconds at 60°C for annealing, and 10 seconds at 70°C for elongation). We verified the microRNA expression by qPCR using U6 snRNA as the internal control with the 2^(-ΔΔCt) method.

2.7 | Statistical analysis

Data analysis was performed in SPSS statistical software version 19.0 (International Business Machines Corporation). The mean ± SD was used to report the data. The chi-square test and ANOVA were used for comparison between groups. \( P < .05 \) was considered statistically significant. The workflow of the experiment is shown in Figure 1.

3 | RESULTS

3.1 | Clinical characteristics of subjects

A total of 40 CAD patients and 10 NCA controls were recruited in the study. The clinical features of the 50 subjects in this study are shown in Table 1. There was a higher prevalence of diabetes and total cholesterol (TC) in the UA group than in the other groups (\( P = .0435 \) and \( P = .0045 \), respectively), whereas high-density lipoprotein cholesterol (HDL-C) level in the NSTEMI patients was significantly higher than in the other groups (\( P < .001 \)). The cardiac troponin I (cTnI) levels in the UA, NSTEMI, and STEMI patients were significantly higher than in the NCA and SA groups (\( P < .001 \)). There were no significant differences in age, sex, smoking, drinking, systolic BP, diastolic BP, hypertension, triglycerides (TG), or low-density lipoprotein cholesterol (LDL-C) between the CAD patients and NCA controls.

3.2 | Overview of the sequencing data

In this study, 50 cDNA libraries were constructed and sequenced. A total of 1871.82 M raw reads were obtained. We first removed low-quality reads: the reads in which (a) more than 50% of bases had a Q value less than or equal to 5; (b) the unable-to-determine-base-information ratio was greater than 10%; (c) there was 5' joint contamination; (d) there was no 3' joint sequence or insert fragment; and (e)
there was a polyA/T/G/C 3’ flanking sequence. After their removal, the clean reads remained. The Q30 ranged between 90.77% and 98.93% for each sample, and more than 90.62% of the total clean reads were mapped. Generally, these results show that the quality of these libraries was good and suitable for analysis. Detailed sequencing data quality information is presented in Table S1 and Table S2.

**TABLE 1** The baseline clinical characteristics

| Variable          | NCA   | SA    | UA    | NSTEMI | STEMI | P value |
|-------------------|-------|-------|-------|--------|-------|---------|
| Age (y)           | 56.0 ± 8.5 | 62.7 ± 11.5 | 60.4 ± 7.2 | 54.3 ± 10.1 | 59.1 ± 9.2 | .5989   |
| Sex (male)        | 5 (50%) | 6 (60%) | 7 (70%) | 6 (60%) | 5 (50%) | .8864   |
| Smoking           | 3 (30%) | 1 (10%) | 2 (20%) | 2 (20%) | 3 (30%) | .8031   |
| Drinking          | 1 (10%) | 0 (0%) | 1 (10%) | 0 (0%) | 0 (0%) | .5371   |
| Systolic BP (mm Hg) | 132.4 ± 10.9 | 130.1 ± 14.2 | 129.4 ± 13.4 | 138.7 ± 16.8 | 124.2 ± 18.4 | .9111   |
| Diastolic BP (mm Hg) | 85.1 ± 11.4 | 81.2 ± 12.5 | 77.3 ± 6.4 | 83.0 ± 10.9 | 79.3 ± 10.7 | .3902   |
| Hypertension      | 2 (20%) | 3 (30%) | 7 (70%) | 4 (40%) | 5 (50%) | .1936   |
| Diabetes          | 1 (10%) | 0 (0%) | 4 (40%) | 0 (0%) | 3 (30%) | .0435   |
| Hyperlipidemia    | 4 (40%) | 1 (10%) | 5 (50%) | 5 (50%) | 2 (20%) | .2081   |
| TC, mmol/L        | 1.34 ± 0.57 | 1.17 ± 0.58 | 2.24 ± 0.87 | 1.94 ± 1.73 | 1.65 ± 1.13 | .0045   |
| TG, mmol/L        | 4.54 ± 0.86 | 4.46 ± 0.60 | 4.41 ± 0.61 | 5.57 ± 1.34 | 4.53 ± 0.97 | .8640   |
| HDL-C, mmol/L     | 1.21 ± 0.41 | 1.24 ± 0.23 | 0.95 ± 0.21 | 1.30 ± 0.40 | 1.05 ± 0.07 | .0083   |
| LDL-C, mmol/L     | 2.39 ± 0.53 | 2.53 ± 0.55 | 2.50 ± 0.52 | 3.32 ± 1.31 | 2.88 ± 1.02 | .9018   |
| cTnI, µg/L        | 0.013 ± 0.037 | 0.009 ± 0.025 | 2.268 ± 7.109 | 2.274 ± 4.428 | 5.945 ± 9.124 | .0142   |
| BNP, pg/L         | 392.56 ± 949.10 | 694.63 ± 1094.89 | 1590.44 ± 4760.54 | 1782.83 ± 3926.01 | 2579.71 ± 2950.41 | .0874   |

Abbreviations: BNP, brain natriuretic peptide; cTnI, cardiac troponin I; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
3.3 | Differentially expressed microRNAs in plasma

MicroRNAs were analyzed with strict data quality control, and a total of 2135 microRNAs were found. To systematically study the level of microRNA expression associated with CAD, 40 patients with CAD and 10 NCA controls were analyzed in this study. The differences between the CAD patients and the NCA controls are shown in Figure 2. The blue and red in the picture indicate that the relative expression was reduced and raised, respectively.

Volcano plots were made to evaluate microRNAs between CAD patients and NCA controls (Figure 3). Compared to NCA, 159 differentially expressed microRNAs were discriminated in CAD patients, including 119 upregulated microRNAs and 40 downregulated microRNAs (P < .05). The top 10 upregulated miRNAs were miR-144-3p, miR-34a-5p, miR-15b-3p, miR-22-3p, miR-29b-3p, miR-1270, miR-6891-5p, miR-106a-5p, miR-15b-5p, and hsa-miR-499b-3p. The top ten downregulated miRNAs were miR-4437, miR-6842-3p, miR-4664-3p, miR-671-3p, miR-219a-1-3p, miR-7848-3p, miR-664a-3p, miR-1284, miR-361-3p, and miR-6780a-5p. In the SA group, UA group, NSTEMI group, and STEMI group, there were 0, 12, 20, and 25 downregulated microRNAs compared with NCA controls, respectively. Therewere 0, 12, 20, and 25 downregulated microRNAs compared with NCA controls, respectively. The details are shown in Venn diagrams of upregulated and downregulated differentially expressed microRNAs in CAD patients (Figure 4). Moreover, a horizontal comparison of microRNA expression was also performed at the overall level, and the trend changes of the altered expression profiles of 99 microRNAs were in accordance with the extent of CAD, as shown in Figure 5.

3.4 | Gene ontology and KEGG pathway analyses

Gene ontology and KEGG pathway analysis showed that genes were sorted by hierarchical categories according to biological process, cellular component, and molecular function.

Among the identified mRNAs, 19 243 genes were related to biological function (Figure 6). The enriched GO terms of these potential targets included many biological events. The most enriched pathways related to the microRNAs with differential expression were endocytosis, pathways in cancer, focal adhesion, axon guidance, and so on, according to the KEGG pathway analysis (Figure 7). The detailed information on the GO analysis and the top 20 pathways according P value in the KEGG enrichment analysis are shown in Table S3 and Table S4, respectively.

3.5 | qRT-PCR validation of microRNA expression

To confirm the sequencing data of microRNA expression levels, six upregulated microRNAs (has-miR-126-5p, has-miR-20a-5p, has-miR-22-3p, has-miR-29a-3p, has-miR-30e-5p, and has-miR-93-5p) and two downregulated microRNAs (has-miR-3184-3p and has-miR-671-3p) were randomly selected. We confirmed the microRNA expression in the plasma of CAD patients (n = 80) and NCA controls (n = 20) by qRT-PCR using U6 snRNA as the internal control with the 2-ΔΔCt method. Differences in the expression of all eight microRNAs were detected in CAD patients compared with NCA controls, and the results of qRT-PCR were consistent with those of RNA sequencing analysis (Figure 8A).

3.6 | ROC analysis

ROC analysis was done to evaluate the diagnostic value of some differentially expressed microRNAs that were randomly selected for differentiating between CAD patients and NCA controls. MicroRNAs with P < .05 and AUC > 0.6 were selected as potential markers to distinguish CAD patients and NCA controls (Figure 8B). The ROC curves yielded the following AUCs: miR-20a-5p (AUC = 0.892, upregulated), miR-22-3p (AUC = 0.924, upregulated), miR-29a-3p (AUC = 0.920, upregulated), miR-30e-5p (AUC = 0.907, upregulated), miR-93-5p (AUC = 0.944, upregulated), miR-126-5p (AUC = 0.928, upregulated), miR-671-3p (AUC = 0.739, downregulated), and miR-3184-3p (AUC = 0.741, downregulated), which were found to distinguish CAD patients from NCA subjects.

4 | DISCUSSION

Heart disease is the main cause of death for both males and females and is a great burden to some countries, which includes the cost of health care services, medications, and lost productivity.33–36 Before vessel obstruction, the vascular wall has a plaque for a long time, and several cytokines are involved in all stages of the formation and progression of atherogenic plaque, which provides a possibility for the prediction and early diagnosis of cardiovascular adverse events. There is a lack of good biomarkers that could be used in early clinical diagnosis, clinical risk stratification, and evaluation of the prognosis of CAD, and there is a great clinical demand for reliable non-invasive biomarkers for CAD.37,38

Many studies have found that microRNAs are important regulators of the onset and progression of coronary artery disease. In addition, some reports have shown that some microRNAs can be used as diagnostic or prognostic markers for CAD. MicroRNAs are a novel group of conserved non-coding, single-strand small RNAs that regulate gene expression after transcription, leading to translation inhibition or mRNA degradation.39 Many studies have shown that microRNAs participate in many biological processes and speculate that they regulate the expression of 1/3 or more of the genes in animals.40,41 MicroRNAs are not only widely involved in important life processes, such as the normal growth, development, and metabolism of the body, but they also play an important regulatory role in the onset and progression of many diseases. Plasma or serum microRNAs can be biological indicators for early clinical diagnosis, and further exploration of microRNAs in the pathogenesis of some diseases has gotten increasing attention.
globally. These molecules provide a new research field to study early clinical diagnosis, clinical risk-stratified diagnosis, and evaluation of the prognosis of CAD.

We reviewed the relevant literature on microRNAs related to cardiovascular disease and compared the previous results with ours. One study showed that miR-126-5p was not significantly upregulated...
or downregulated in CAD patients, but the level of miR-126-5p was significantly increased in patients whose LDL cholesterol was high.42 Another study indicated that circulating miR-126-5p is a potential biomarker for predicting type 2 diabetes and diabetic CAD.43 One study showed that the level of miR-146a/b was observably increased in the CAD group compared with the non-CAD group.44 The SNP in miR-146a and rs2910164 G>C was significantly associated with an increased risk for CAD.45 Another report has shown that early growth response 2 (EGR2) is regulated by 8 microRNAs, including miR-150. It might play important roles in patients before and after off-pump coronary artery bypass (OPCAB) surgery via the regulation of associated genes.46 Many studies have shown that miR-17-5p is an important regulator in the G1/S phase cell cycle transition.47 miR-17-5p is associated with breast cancer,48,49 lung cancer,50 liver cancer,51 gastric cancer,52 pancreatic cancer,53 and multiple sclerosis54 and may have a role in the onset and progression of heart failure.55 In the present study, we found that miR-17-5p was significantly upregulated in CAD patients. MiR-181a-2-3p has been associated with cerebral cavernous malformations56 and follicular variant of papillary thyroid carcinoma (FVPTC).57 Another study showed that rs174545

**FIGURE 3** Volcano plot of differential microRNA expression. X-axis: log₂(fold change); Y-axis: −1 × log₁₀(corrected q value) for each probe. (Figure 3A: SA vs NCA; Figure 3B: UA vs NCA; Figure 3C: NSTEMI vs NCA; Figure 3D: STEMI vs NCA)
ZHONG et al. (FADS1: miR-181a-2), affecting a microRNA-binding site, can affect microRNA-mediated regulation of cardiometabolic genes.\textsuperscript{58} Our results showed that miR-181a-2-3p was significantly downregulated in CAD patients. One study showed that miR-181a-5p and miR-181b-5p were upregulated in congestive heart failure, and these microRNAs may play a role in the onset and progression of this disease, as they might be related to pathways associated with disease progression.\textsuperscript{55}

A previous study showed that acute heart failure and renal disease were correlated with obviously decreased levels of miR-199a-3p and miR-423-5p compared with healthy controls.\textsuperscript{59} In this study, we found that miR-199a-3p was significantly upregulated in CAD patients and that miR-423-5p was downregulated. A previous study showed that reduced miR-214-3p expression may contribute to MEF2C expression in myocardial hypertrophy.\textsuperscript{60} Some studies have shown that circulating miR-22-3p contains important information about chronic heart failure patients\textsuperscript{61} and participates in regulating the expression of hypertension-related genes and in the development of hypertension.\textsuperscript{62} In our research, we excluded patients with heart failure, and circulating miR-22-3p was significantly upregulated in CAD patients compared with NCA controls. These results show that miR-22-3p may contain important information on the onset, progression, prognosis, and other aspects in patients with cardiovascular disease. A previous study indicated that miR-26b-5p was upregulated in the serum of left ventricular hypertrophy (LVH) hypertensive patients compared with healthy controls.\textsuperscript{63} In our research, circulating miR-26b-5p was significantly upregulated in CAD patients. A previous study indicated that miR-30a-5p and miR-30e-5p may have a role in the onset and progression of heart failure.\textsuperscript{55} In our research, circulating miR-30a-5p and miR-30e-5p were significantly upregulated in CAD patients.

Our results suggested the importance of some microRNAs that have not been reported in the study of cardiovascular disease, including the upregulated miR-100-5p, miR-107, miR-1-3p, miR-152-3p, miR-16-5p, miR-185-5p, miR-186-5p, miR-20a-5p, miR-24-3p, miR-27a-3p, miR-29a-3p, miR-3074-5p, miR-340-5p, miR-363-3p, miR-425-5p, miR-451a, miR-485-3p, and miR-93-5p and the downregulated miR-1228-5p, miR-1246, miR-1273h-3p, miR-3184-3p, miR-589-5p, miR-671-3p, miR-6772-3p, miR-6842-3p, and miR-99b-5p. They may also be used as potential biological markers for CAD. Interestingly, we found three novel microRNAs, miR-3184-3p, miR-451a, and miR-6772-3p. The research on the functions of these microRNAs will be the focus of our next work.

The enriched GO terms of these potential target genes related to the differentially expressed microRNAs involved some basic biological processes, such as intracellular, extracellular vesicle, and protein-DNA complex assembly. In KEGG pathway analysis, the most

FIGURE 4 Venn diagrams of differentially upregulated microRNAs (A) and differentially downregulated microRNAs (B) in CAD patients

FIGURE 5 Hierarchical clustering of differentially expressed microRNAs in CAD patients and NCA controls. The red and green shades indicate upregulated and downregulated microRNAs, respectively, across all samples
enriched pathways among the differentially expressed microRNAs were endocytosis, pathways in cancer, focal adhesion, axon guidance, and so on. These microRNAs may have a role in the pathways related to disease progression.

Our study was on the microRNA expression profiles in the Chinese Hakka population, but there are still some shortcomings to our research. The number of subjects in this study was low. In addition, there may be differences in the results of patients from different regions and races. Therefore, these results need to be verified in a larger number of people. Again, the functions of these microRNAs have not yet been determined. More detailed studies are needed to determine the biological effects of the microRNAs.

5 | CONCLUSIONS

This study comprehensively identified and analyzed microRNA expression in CAD patients using RNA sequencing. The results
suggested that the expression levels of some microRNAs may play a vital role in the onset and course of progression of CAD. This discovery might provide useful information for the diagnosis and treatment of CAD. The function of the corresponding microRNAs will be the focus of our next work.

ACKNOWLEDGMENTS

This study was supported by Key Scientific and Technological Project of Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Guangdong Province, China (Grant No.: MPHKSTP-20170101 to Prof. Zhixiong Zhong) and Key Scientific and Technological Project of Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Guangdong Province, China (Grant No.: MPHKSTP-20180101 to Prof. Zhixiong Zhong).

AUTHOR CONTRIBUTIONS

Zhixiong Zhong, Heming Wu, and Wei Zhong designed the study. Zhixiong Zhong and Heming Wu performed the experiments. Wei Zhong and Qifeng Zhang recruited subjects and collected clinical data. Qunji Zhang and Zhikang Yu helped to analyze the data. Heming Wu prepared the manuscript. All authors were responsible for critical revisions, and all authors read and approved the final version of this work.

DATA AVAILABILITY STATEMENT

The data used to support the findings of this study are available from the corresponding author upon request.

ORCID

Zhixiong Zhong https://orcid.org/0000-0002-3200-3105
Heming Wu https://orcid.org/0000-0002-1876-9585

REFERENCES

1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med. 1994;331(8):496-501.
2. Posadasánchez R. Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. Nature. 2005;360(5938):5.
3. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on C. Circulation. 2006;114(16):1761-1791.
4. Bugiardini R. Risk stratification in acute coronary syndrome: focus on unstable angina/non-ST segment elevation myocardial infarction. Heart. 2004;90(7):729-731.
5. Lakhani MS, Qadir F, Hanif B, Farooq S, Khan M. Correlation of thrombolysis in myocardial infarction (TIMI) risk score with extent of coronary artery disease in patients with acute coronary syndrome. J Pak Med Assoc. 2010;60(3):197-200.
6. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe 2016: an epidemiological update. Eur Heart J. 2016;37(42):3182-3183.
7. Libby P, Bornfeldt KE, Tall AR. Atherosclerosis: successes, surprises, and future challenges. Circ Res. 2016;118(4):531-534.
8. García DTJ. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):429-430.
9. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis. 2006;17(8):699-706.
10. Kaptoge S, Seshasai SRK, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578-589.
11. Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy. 2003;2(3):257-265.
12. Autieri MV. Pro- and anti-inflammatory cytokine networks in atherosclerosis. Isr Vasc Med. 2012;2012(6):329-341.
13. Ramji DP, Davies TS. Cytokines in atherosclerosis: key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015;26(6):673-685.
14. Mirzaei H, Gholamin S, Shahidzadeh S, et al. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur J Cancer. 2016;53:25-32.
15. Gholamin S, Pasdar A, Sadegh Khorrami M, et al. The potential for circulating microRNAs in the diagnosis of myocardial infarction: a
16. Simonian M, Mosaliayi M, Mirzaei H. Circulating miR-21 as novel biomarker in gastric cancer: diagnostic and prognostic biomarker. J Cancer Res Ther. 2018;14(2):475.

17. Mirzaei H, Sahebkar A, Mohammadi M, et al. circulating microRNAs in hepatocellular carcinoma: potential diagnostic and prognostic biomarkers. Curr Pharm Des. 2016;22(34):5247-5269.

18. Salarinia R, Sahebkar A, Peyvandi M, et al. Epi-drugs and Epi-miRs: moving beyond current cancer therapies. Curr Cancer Drug Targets. 2016;16(9):773-788.

19. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol. 2004;2(11):e363.

20. Liao XB, Perez VA, Krol M, Yeh CH, Yuan LQ. MicroRNA and cardiovascular disease. Biomed Res Int. 2015;2015:734380.

21. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838.

22. Liu NK, Xu XM. MicroRNA in central nervous system trauma and degenerative disorders. Physiol Genomics. 2011;43(10):571-580.

23. Liu CK. Cardiovascular diseases in China. Eur J Immuinol. 2010;40(3):888-894.

24. Small EM, Frost RJ, Olson EN. MicroRNA therapeutics for cardiovascular disease. Nat Rev Drug Discov. 2012;11(11):860-872.

25. Liao XB, Perez VA, Krol M, Yeh CH, Yuan LQ. MicroRNA and cardiovascular disease. Biomed Res Int. 2015;2015:734380.

26. Small EM, Frost RJ, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012;11(11):860-872.

27. Rooij EV, Olson EN. MicroRNA and cardiovascular disease. Biomed Res Int. 2015;2015:734380.

28. Shantikumar S, Caporali A, Emanueli C. Role of miRNAs in human heart disease. Physiol Genomics. 2007;31(3):367-373.

29. Shantikumar S, Caporali A, Emanueli C. Role of miRNAs in diabetes and its cardiovascular complications. Cardiovasc Res. 2012;93(4):583-593.

30. Al-­Kafaji G, Al-Mahroos G, Abdulla Al-Muhtaresh H, Sabry MA, Abdul Razzaq R, Salem AH. Circulating endothelium-enriched microRNA-126 as a potential biomarker for coronary artery disease in type 2 diabetes mellitus patients. Biomarkers. 2017;22(3-4):268-278.

31. Al-­Kafaji G, Al-Mahroos G, Abdulla Al-Muhtaresh H, Sabry MA, Abdul Razzaq R, Salem AH. Circulating endothelium-enriched microRNA-126 as a potential biomarker for coronary artery disease in type 2 diabetes mellitus patients. Biomarkers. 2017;22(3-4):268-278.

32. Kanehisa M, Araki M, Goto S, et al. KEGG for linking genomics to life. Nucleic Acids Res. 2008;36:D480-484.

33. Liu CK. Cardiovascular diseases in China. Am J Cardiol. 1962;10(3):367-370.

34. Nichols M, Townsend N, Scarborough P, Rayner M. European Cardiovascular Disease Statistics 2012. Eur Heart J. 2013;34(39). Available from: http://www.ghdonline.org/projects/euroheart-ii/euroheart-ii-publications/673:.html

35. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2014 update a report from the American heart association. Circulation. 2014;129(3):e28-e292.

36. Chen WW, Gao RL, Liu LS, et al. China cardiovascular diseases report 2015: a summary. J Geriatr Cardiol. 2017;14(1):1-10.

37. Shaw LJ, Raggi P, Berman DS, Callister TQ. Cost effectiveness of screening for cardiovascular disease with measures of coronary calcium. Prog Cardiovasc Dis. 2003;46(2):171-184.

38. Demer LL, Tintut Y. Vascular calcification pathobiology of a multifaceted disease. Circulation. 2008;117(22):2938-2948.

39. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.

40. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are miRNA targets. Cell. 2005;120(1):15-20.

41. Friedman RC, Farh KH, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92-105.

42. Sun X, Zhang M, Sanagawa A, et al. Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol. Thromb J. 2012;10(1):16.

43. Al-Kafaji G, Al-Mahroos G, Abdulla Al-Muhtaresh H, Sabry MA, Abdul Razzaq R, Salem AH. Circulating endothelium-enriched microRNA-126 as a potential biomarker for coronary artery disease in type 2 diabetes mellitus patients. Biomarkers. 2017;22(3-4):268-278.

44. Takahashi Y, Saitoh M, Minami Y, Tabuchi T, Itoh T, Nakamura M. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and toll-like receptor 4 levels. Clin Sci. 2010;119(9):395-405.

45. Xiong X-D, Cho M, Cai X-P, et al. A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression. Mutat Res. 2014;761:15-20.

46. Chen WW, Gao RL, Liu LS, et al. miR-20a: molecular markers for gastric cancer. Mol Cancer. 2016;21:8191-8201.

47. Liu CK. Cardiovascular diseases in China. Am J Cardiol. 1962;10(3):367-370.

48. Kanehisa M, Araki M, Goto S, et al. KEGG for linking genomics to life. Nucleic Acids Res. 2008;36:D480-484.

49. Liu CK. Cardiovascular diseases in China. Am J Cardiol. 1962;10(3):367-370.

50. Nichols M, Townsend N, Scarborough P, Rayner M. European Cardiovascular Disease Statistics 2012. Eur Heart J. 2013;34(39). Available from: http://www.ghdonline.org/projects/euroheart-ii/euroheart-ii-publications/673:.html

51. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2014 update a report from the American heart association. Circulation. 2014;129(3):e28-e292.

52. Chen WW, Gao RL, Liu LS, et al. China cardiovascular diseases report 2015: a summary. J Geriatr Cardiol. 2017;14(1):1-10.

53. Shaw LJ, Raggi P, Berman DS, Callister TQ. Cost effectiveness of screening for cardiovascular disease with measures of coronary calcium. Prog Cardiovasc Dis. 2003;46(2):171-184.

54. Demer LL, Tintut Y. Vascular calcification pathobiology of a multifaceted disease. Circulation. 2008;117(22):2938-2948.

55. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.

56. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are miRNA targets. Cell. 2005;120(1):15-20.
59. Bruno N, ter Maaten JM, Ovchinnikova ES, et al. MicroRNAs relate to early worsening of renal function in patients with acute heart failure. *Int J Cardiol*. 2016;203:564-569.

60. Tang C-M, Liu F-Z, Zhu J-N, et al. Myocyte-specific enhancer factor 2C: a novel target gene of miR-214-3p in suppressing angiotensin II-induced cardiomyocyte hypertrophy. *Sci Rep*. 2016;6:36146.

61. van Boven N, Akkerhuis KM, Anroedh SS, et al. Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: the Bio-SHiFT study. *Int J Cardiol*. 2017;235:124-132.

62. Kriegel AJ, Baker MA, Liu Y, Liu Jr P, Cowley Jr AW, Liang M. Endogenous microRNAs in human microvascular endothelial cells regulate mRNAs encoded by hypertension-related genes. *Hypertension*. 2015;66(4):793-799.

63. Kaneto CM, Nascimento JS, Moreira M, et al. MicroRNA profiling identifies miR-7-5p and miR-26b-5p as differentially expressed in hypertensive patients with left ventricular hypertrophy. *Braz J Med Biol Res*. 2017;50(12):e6211.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Zhong Z, Zhong W, Zhang Q, Zhang Q, Yu Z, Wu H. Circulating microRNA expression profiling and bioinformatics analysis of patients with coronary artery disease by RNA sequencing. *J Clin Lab Anal*. 2020;34:e23020. [https://doi.org/10.1002/jcla.23020](https://doi.org/10.1002/jcla.23020)